Inventor · disambiguated record
Petra Oehm
Also filed as: OEHM PETRA
3 granted patents·10 pending applications·4 citations·filing 2016–2024
57Inventor score
Top patents by PatentIndex Score
13 records- 0179US11713346B2Claudin-18.2-specific immunoreceptors and T cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2016·Granted Aug 1, 2023·2 cites·28 claims
- 0274US11702631B2Antigen receptors and uses thereofBIONTECH CELL & GENE THERAPIES GMBH·Filed 2018·Granted Jul 18, 2023·2 cites·15 claims
- 0370US2024287155A1Rna replicon for expressing at cell receptor or an artificial t cell receptorBIONTECH CELL & GENE THERAPIES GMBH·Filed 2023·Application pending·0 cites
- 0469US2024263232A1Methods for characterizing loss of antigen presentationBioNTech SE·Filed 2024·Application pending·0 cites
- 0567US2023303656A1Claudin-18.2-specific immunoreceptors and t cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2023·Application pending·0 cites
- 0659US2025025505A1Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancerBioNTech SE·Filed 2022·Application pending·0 cites
- 0758US11920194B2Methods for characterizing loss of antigen presentationBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2018·Granted Mar 5, 2024·0 cites·23 claims
- 0855US2020283497A1Rna replicon for expressing at cell receptor or an artificial t cell receptorBIONTECH CELL & GENE THERAPIES GMBH·Filed 2018·Application pending·0 cites
- 0951US2025339533A1Agents and methods for activation and targeting of immune effector cellsBIONTECH CELL & GENE THERAPIES GMBH·Filed 2022·Application pending·0 cites
- 1048US2023000962A1Treatment involving immune effector cells genetically modified to express antigen receptorsBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
- 1146US2023405046A1Antigen-specific t cell receptors and t cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2021·Application pending·0 cites
- 1245US2022125836A1Treatment involving car-engineered t cells and cytokinesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
- 1341US2022184119A1Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancersBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →